Skip to main content
Midas Edge

BRAINSTORM CELL THERAPEUTICS INC.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

BCLI$1.14-7.3%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Changes in Stockholders’ Equity

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​ · ​ ​ ​ · Number · ​ ​ ​ · Amount · ​ ​ ​ · capital · ​ ​ ​ · stocks · ​ ​ ​ · deficit · ​ ​ ​ · equity
Balance as of January 1, 20244,032,614​$13​$210,258​​(116)​$(215,013)​$(4,858)
​​​​​​​​​​​​​​​​​​
Stock-based compensation related to stock granted to service providers​9,893​​—​​52​​—​​—​​52
Stock-based compensation related to stock and options granted to directors and employees107,638​​*​​698​​—​​—​​698
Issuance of shares in at-the-market (ATM) offering (Note 8)​1,250,876​​1​​4,322​​—​​—​​4,323
Issuance of shares for private placement (Note 8)​740,741​​*​​3,644​​—​​—​​3,644
Net loss—​​—​​—​​—​​(11,623)​​(11,623)
​​​​​​​​​​​​​​​​​​
Balance as of December 31, 20246,141,762​​14​​218,974​​(116)​​(226,636)​​(7,764)
  • Represents an amount less than $1.

The accompanying notes are an integral part of the consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​ · ​ ​ ​ · Number · ​ ​ ​ · Amount · ​ ​ ​ · capital · ​ ​ ​ · stocks · ​ ​ ​ · deficit · ​ ​ ​ · equity
Balance as of January 1, 20256,141,762​$14​$218,974​​(116)​$(226,636)​$(7,764)
​​​​​​​​​​​​​​​​​​
Stock-based compensation related to stock and options granted to directors and employees658,666​​*​​1,520​​—​​—​​1,520
Issuance of shares in at-the-market (ATM) offering (Note 8)​2,571,714​​1​​4,346​​—​​—​​4,347
Debt-for-Equity Swap281,250​​*​​450(**)​—​​—​​450
Exercise of warrants (Note 8)1,381,383​1​1,768​—​—​1,769
Net loss—​​—​​—​​—​​(10,307)​​(10,307)
​​​​​​​​​​​​​​​​​​
Balance as of December 31, 202511,034,775​​16​​227,058​​(116)​​(236,943)​​(9,985)
*Represents an amount less than $1.
**During the reporting period, the Company settled outstanding accounts payable to a supplier in the amount of $450 through the issuance of 281,250 shares of common stock. This transaction was accounted for as a debt-for-equity swap.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.